RRMS Patients May Try Stem Cell Therapy if Lemtrada Fails

Lemtrada Stroke Lawsuit News

Even though Lemtrada is considered a drug of last resort RRMS patients may look to stem cell therapy to replace and improve their immune systems

Thursday, December 26, 2019 - Patients that experience a relapse of their multiple sclerosis symptoms after taking the controversial drug Lemtrada can look to stem cell therapy for a potential solution. With stem cell therapy the patient's bone marrow is harvested and treated with chemotherapy to remove the MS cells. After the harvesting, the patient's remaining immune system is ablated with steroids and strong chemotherapy and the new bone marrow is returned via a simple intravenous injection. Stem cell therapy is performed in a hospital in sterile conditions. The stem cell patient normally spends around two weeks in the hospital in what is called a Laminar airflow room. A Laminar airflow hospital room is less strict than a sterile bubble and simply blows air from behind the patient who remains "upwind" from any visitors who must scrub up and put on a sterile mask, gown, and gloves. Recovery time from stem cell therapy can take around three months of physical therapy to rebuild the patient's strength. A patient may be let out of the hospital when their blood counts show a strengthened immune system.

According to the National MS Society "stem cell therapy has produced encouraging results in almost 70% of those given the treatment." These patients "didn't have a relapse in RRMS symptoms or new brain lesions, which are caused by MS, 5 years after treatment." Clinical trials are being conducted and physicians should refer a patient that wishes to participate. Infection and graft rejection are potentially deadly adverse consequences of stem cell therapy. Lemtrada stroke attorneys offer a free consultation and no obligation to file a lawsuit claim.

Lemtrada has severe, life-threatening side effects that can cause additional problems that stem cell therapy cannot address such as causing a stroke or heart attack. Lemtrada complications can occur quickly, within one to three days after receiving the drug in the form of an IV drip. Lemtrada patients report cases of arterial dissection that leads to a stroke occurring within 24 hours of receiving a Lemtrada infusion.

Multiple sclerosis is described as when the body's immune system attacks the Myelin sheathing that covers the nerves and gradually leaves them more and more exposed to unintended stimuli. The symptoms or relapse-remitting multiple sclerosis (RRMS) can seem like nothing at first but can quickly advance to one being unable to walk. RRMS patients report that after initial difficulty with balance and fatigue they feel numbness in the extremities. This numbness can quickly include the entire lower half of the body and can make walking difficult, like when your foot or leg falls asleep. Drugs to treat RRMS can be effective for a while and then suddenly stop working adding to one's fears and sense of hopelessness. Those suffering from advanced stage RRMS take Lemtrada to help alleviate the symptoms of the disease and to lengthen the periods of remission between episodes.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.